Type: Multi-Center Trial
Purpose: To evaluate the efficacy of two doses of GLPG1690 in addition to local standard of care compared to placebo in subjects with idiopathic pulmonary fibrosis (IPF) as evaluated by the rate of decline of forced vital capacity (FVC) over a period of 52 weeks.
Dates: November 5, 2018 - December 15, 2021
Disease: Pulmonary Fibrosis
Page last updated: April 10, 2020